Latest Legal Developments News

The Supreme Court of Western Australia has cleared the way for Superior Resources to resume trading by validating a contentious share issue from October 2025. This legal resolution lifts previous restrictions, allowing the company’s shares to be freely traded on the ASX once again.

Besra Gold Inc has updated its Bau Gold Project resource to 2.28 million ounces and is intensifying efforts to renew a critical mining lease, signaling a strategic reset for the company.

Volt Resources has secured strategic funding and relocated its US operations to Alabama, advancing its graphite refinery ambitions while winning a key legal battle in Ukraine.

Latrobe Magnesium successfully commissioned its Demonstration Plant producing magnesium oxide and secured $10 million in funding, while receiving a $200 million financing interest from the U.S. Export Import Bank for its next-stage commercial plant.

Tesoro Gold has reported a significant 42% increase in its Ternera gold resource alongside a robust scoping study and a $34 million equity raise to accelerate development of its El Zorro project in Chile.

Regis Resources reported a solid September quarter with 90.4koz gold production and a $158 million increase in cash and bullion. Key underground projects at Garden Well Main and Rosemont Stage 3 began ore production, supporting steady FY26 guidance.

29Metals reports a steady copper output but significant zinc production decline due to seismic disruptions at Golden Grove, alongside rising operational costs and ongoing progress at Capricorn Copper.

Carawine Resources Limited’s shares have been suspended from trading following a Federal Court ruling that allows QGold Pty Ltd to compulsorily acquire all remaining shares it does not own.

ASIC has initiated civil proceedings against Fiducian’s subsidiary, alleging misleading statements and compliance failures related to a now-closed investment fund. Fiducian is cooperating but remains tight-lipped as the case unfolds.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

Mayne Pharma reported a robust 5% revenue increase to $408.1 million and more than doubled its underlying EBITDA to $47 million in FY25, driven by strong Women’s Health sales and strategic acquisitions in Dermatology.

The Federal Court of Australia has dismissed Harvey Norman’s appeal against prior legal declarations, setting the stage for an upcoming penalty hearing that could impact the retailer’s future.